Valuation: ME Therapeutics Holdings Inc.

Market Cap 75.97M 54.45M 48.76M 44.86M 40.64M 5.17B 77.39M 535M 215M 2.72B 204M 200M 8.58B P/E 2024
-51.7x
P/E 2025 -93.2x
Enterprise Value 74.64M 53.49M 47.91M 44.07M 39.93M 5.08B 76.04M 526M 211M 2.67B 201M 196M 8.43B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
44.63%
Yield 2024 *
-
Yield 2025 -
1 week+3.77%
Current month-60.71%
1 month-60.71%
3 months-56.00%
6 months-56.00%
Current year-72.50%
1 week 1.1
Extreme 1.1
1.1
1 month 0.95
Extreme 0.95
2.8
Current year 0.79
Extreme 0.79
4.1
1 year 0.79
Extreme 0.79
5.35
3 years 0.05
Extreme 0.05
11
5 years 0.05
Extreme 0.05
11
10 years 0.05
Extreme 0.05
11
Manager TitleAgeSince
Chief Executive Officer 46 09/03/2023
Director of Finance/CFO 44 09/03/2023
Corporate Officer/Principal - 25/10/2024
Director TitleAgeSince
Director/Board Member 60 09/03/2023
Director/Board Member 46 09/03/2023
Director/Board Member 59 09/03/2023
Date Insider Type Main position Quantity % Market Cap. Importance
16/07/26 Option

Director

294,118 0.9788%
16/07/26 Sell

Director

294,118 0.9788%
16/07/26 Option

Chief Financial Officer

125,000 0.4160%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+3.77%-78.00%+75.30% 23.91M
-0.62%-1.87%+46.31%+56.99% 64.38B
+0.35%+3.20%+14.92%+84.55% 56.16B
+0.53%+1.96%+15.37%+106.81% 54.16B
-2.81%-4.31%+23.50%+50.90% 45.33B
-0.33%-1.93%+20.15%+98.45% 42.25B
+0.55%+2.31%+224.97%+942.56% 40.78B
+3.27%+47.96%+112.67%+96.48% 33.8B
+1.22%-1.44%+14.89%+47.15% 32.25B
+0.89%+20.55%-42.03%+373.03% 24.37B
Average +0.31%+6.64%+35.27%+193.22% 39.35B
Weighted average by Cap. +0.16%+4.83%+48.30%+185.47%

Financials

2024 2025
Net sales - -
Net income -1.29M -928K -831K -764K -693K -88.1M -1.32M -9.12M -3.66M -46.34M -3.48M -3.41M -146M -1.19M -855K -766K -704K -638K -81.2M -1.22M -8.4M -3.37M -42.71M -3.21M -3.14M -135M
Net Debt -1.5M -1.07M -961K -884K -801K -102M -1.52M -10.54M -4.23M -53.58M -4.03M -3.94M -169M -1.33M -954K -854K -786K -712K -90.59M -1.36M -9.37M -3.76M -47.65M -3.58M -3.5M -150M
Projected Income Statement - Annual - ME Therapeutics Holdings Inc.
Logo ME Therapeutics Holdings Inc.
ME Therapeutics Holdings Inc. is a preclinical stage biotechnology company involved in the discovery and development of novel immune oncology therapeutics targeting immune suppression in cancer. The Company’s focus is on overcoming the suppressive effects of a class of immune cells called myeloid cells to enhance anti-cancer immunity. The Company’s lead candidate is a novel high affinity antibody drug that targets a key protein involved in the generation of suppressive myeloid cells. In addition to its antibody drug candidate program, the Company is also developing a novel small molecule prodrug candidate designed to specifically target suppressive myeloid cells in the tumor environment. The Company has initiated design and testing of two new mRNA-based cancer therapeutic drug candidates.
Employees
-
Date Price Change Volume
29/10/26 CA$1.100 +3.77% 200
  1. Stock Market
  2. Stocks
  3. METX Stock